Is AbbVie's Imbruvica concerned about AZ's rising Calquence? We've got this covered, execs say

1st November 2019 Uncategorised 0

AbbVie has a lot on its plate with an Allergan megamerger in the works and a new rollout for blockbuster hopeful Rinvoq. One thing it hasn’t had to worry about much is its blood cancer franchise—and, despite a rising challenger in AstraZeneca’s Calquence, AbbVie execs still aren’t concerned.

More: Is AbbVie's Imbruvica concerned about AZ's rising Calquence? We've got this covered, execs say
Source: fierce